All In Biotech

Free tool

FAERS Monitor: Pertzye

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 022175 or its brand name (Pertzye, Pancrelipase (Amylase, Lipase, Protease)). Reports on generic versions are filed under their own applications.

Reports

3,036

Serious

2,620

86% of reports

Hospitalization

1,759

Death reported

297

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • diarrhoea262
  • nausea173
  • dyspnoea148
  • fatigue144
  • infective pulmonary exacerbation of cystic fibrosis137
  • off label use134
  • vomiting132
  • pneumonia130
  • abdominal pain122
  • cough120
  • pyrexia120
  • asthenia117
  • weight decreased112
  • pain101
  • drug ineffective98

Reports by year received

View as table
YearReports
200422
200516
200610
200713
200812
200921
201045
201149
201251
201365
201462
2015101
2016123
2017121
2018189
2019297
2020278
2021259
2022297
2023293
2024295
2025277
2026140

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,123 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
infective pulmonary exacerbation of cystic fibrosisSignal137178.9151.523,454
abdominal painSignal1223.63.1233
coughSignal1203.02.5156
diarrhoeaSignal2622.82.5314
pneumoniaSignal1302.82.4149
weight decreasedSignal1122.82.3128
pyrexiaSignal1202.42.098
astheniaSignal1172.21.873
vomiting1321.91.661
dyspnoea1481.81.554
nausea1731.51.331
fatigue1441.31.19
pain1011.10.92
off label use1341.10.90
drug ineffective980.50.447

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.